Clinical Trials Logo
  1. Home
  2. Pancreatic Cancer Non-resectable
  3. NCT05047991

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer Non-resectable Clinical Trial

Official title:
A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase II Study to Evaluate the Differences of Safety and Efficacy of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Clinical Trial Summary

This is a multicenter, randomized, open-lable, parallel-controlled phase II study of irinotecan liposome injection-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma. The purpose of this study is to evaluate the differences of safety and efficacy of irinotecan liposome injection-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma.

Clinical Trial Description

This is a multicentre randomized, open-label, parallel-controlled, phase II study to evaluate the efficacy and safety of irinotecan liposome injection-containing regimens. Eligible patients will be randomly divided into two cohorts at a ratio of 2:1. The patients in cohort 1 (the experimental group) will receive irinotecan liposome injection combined with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin.The patients in cohort 2 (the control group) will receive nab-paclitaxel plus gemcitabine. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05047991
Study type Interventional
Source CSPC Ouyi Pharmaceutical Co., Ltd.
Contact Jihui Hao, Ph.D
Phone 86-18622221120
Email haojihui@tjmuch.com
Status Not yet recruiting
Phase Phase 2
Start date October 2021
Completion date November 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02128100 - Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer Phase 2
Completed NCT03590275 - Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX
Recruiting NCT05265663 - Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients N/A
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Recruiting NCT06160323 - Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer N/A
Active, not recruiting NCT04156087 - Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT03941093 - Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer Phase 3
Recruiting NCT03165591 - Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05549414 - Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System N/A
Not yet recruiting NCT06375967 - EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) N/A
Withdrawn NCT04852367 - PanDox: Targeted Doxorubicin in Pancreatic Tumours Phase 1
Recruiting NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Phase 2
Recruiting NCT03964064 - I125 Seed Implantation vs Stereotactic Radiotherapy for Pancreatic Cancer N/A
Not yet recruiting NCT06361030 - Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT05424159 - Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer N/A
Terminated NCT01887041 - Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer Phase 4
Active, not recruiting NCT03984214 - Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer Phase 3
Recruiting NCT05262452 - Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer N/A
Recruiting NCT04986930 - mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma Phase 2
Recruiting NCT04116073 - INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer Phase 2